en · de · es · fr · pt
sr9009-notes.peptides5388.com › Guide › Sr9009 Background And Receptor Mechanism — Field Notes

Sr9009 Background And Receptor Mechanism — Field Notes

By Editorial Desk · published 2025-12-16 · last reviewed 2026-02-01 · Guide

A practical reference on REV-ERB: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2026-02-01. Anything still debated is marked as such rather than presented as settled.

SR9009 Background and Receptor Mechanism

Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.

SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.

SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.

Analytical Detection and Regulatory Status

Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.

Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistSmall-molecule nuclear receptor ligand
AppearanceOff-white to pale yellow solidTypical for research-grade powder
Solubility classSoluble in DMSO; low water solubilityCommon stock solutions use organic solvent
Typical stock solventDimethyl sulfoxideUsed for laboratory assays
Common analytical methodHPLC with UV or mass detectionUsed for identity and purity checks

Analytical Detection and Storage

Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.

Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.

Related pages on this site

SR9009 Identity and Mechanism

REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.

SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.

SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.

Notes from published material

Spanish descendants in the Masonic exile community with lighter skin tones successfully integrated into Miami, but more trouble was faced by those Afrocuban black and mixed-race members living in the Deep South during the era of Racial segregation in the United States. Where Freemasonry in Cuba had allowed black members since 1868, some of the Lodges in the United States did not allow nonwhite members. After escaping to Florida, Tarajano-Gonzalez issued a declaration that any activities of the Grand Lodge of Cuba would be considered "irregular" and "unlawful" according to their own Masonic tradition, and established the Grand Lodge of Cuba in Exile (Spanish: Gran Logia de Cuba En el Exterior), within the territorial jurisdiction of the Grand Lodge of Florida. They claimed that it was not possible for Freemasonry to exist in a country under a Communist government. They further claimed that the majority of the officers of the Grand Lodge of Cuba had become exiled in the United States. On March 6, 1961, the Grand Lodge in Exile was recognized and granted permission by Edwin Larson, Grand Master of Masons in Florida. On March 15, 1962, the Grand Lodge of Florida proclaimed that they did not recognize any authority of the Freemasons in Cuba, unless those acts were approved by the Grand Master of Masons in Cuba in Exile. In 1963, Grand Master John T. Rose, Jr. of the Grand Lodge of Florida issued an edict which stated their recognition that Grand Master Tarajano-Gonzalez was the only recognized Grand Master of Masons in Cuba.

== World Accreditation Day (WAD) == NABL celebrates World Accreditation Day (WAD) every year on 9 June. World accreditation day is celebrated to provide awareness on accreditation and how accreditation benefits its stakeholders.

Isolated cataplexy unto itself (i.e., in the absence of characteristically associated narcolepsy), admittedly a rare condition There is anecdotal and tentative, as-yet-undocumented information suggesting that clomipramine may address certain core features of hyperacusis, and possibly misophonia. In the case of hyperacusis, this appears to be especially the case at doses > 150 mg/d. As-with obsessive-compulsive disorder, a full response to any one dose may not be experienced for up to 12–16 weeks. Although lithium is most-associated with the treatment of bipolar disorder (where it is known for its general mood-stabilising features and to be especially useful in treating and preventing mania), it may have a certain place in the management of treatment-resistant depression (which is often of higher severity than other depressions which have not been addressed with ECT). In these cases it is often prescribed alongside SSRIs (e.g., fluoxetine, paroxetine), venlafaxine and various of the tricyclics (e.g., clomipramine, amitriptyline, nortriptyline, maprotiline), which is why it may feature sometimes in the discussion of depression being managed with clomipramine. Lithium also significantly reduces the long-term risk of suicide in general. In any case, it is not necessary to have a diagnosis of bipolar affective disorder (manic-depressive illness), or even to be considered to have subtle elements of it ("soft bipolarity"), to benefit from lithium in the context of treatment with clomipramine.

Despite his clean energy policies and congressional Republicans characterizing them as a "War on American Energy", domestic oil production reached a record high in October 2023. Biden has said the U.S. needs to "get tough" on China, calling it the "most serious competitor" that poses challenges to the United States' "prosperity, security, and democratic values". Biden has spoken about human rights abuses in the Xinjiang region to Chinese leader Xi Jinping, pledging to sanction and commercially restrict Chinese government officials and entities who carry out repression. Biden has said he is against regime change but is for providing non-military support to opposition movements. He opposed direct U.S. intervention in Libya, voted against U.S. participation in the Gulf War, voted in favor of the Iraq War, and supports a two-state solution in the Israeli–Palestinian conflict. Biden pledged to end U.S. support for the Saudi Arabian-led intervention in Yemen and to reevaluate the United States' relationship with Saudi Arabia. Biden supported extending the New START arms control treaty with Russia to limit the number of nuclear weapons deployed by both sides. In 2021, Biden officially recognized the Armenian genocide, becoming the first U.S. president to do so. Biden supported abortion rights throughout his presidency, though he personally opposes abortion because of his Catholic faith. In 2019, he said he supported Roe v. Wade and repealing the Hyde Amendment. After Dobbs v.

Sources: en.wikipedia.org

Background from the literature

==== Tuberculosis ==== Once engulfed by a macrophage, the causative agent of tuberculosis, Mycobacterium tuberculosis, avoids cellular defenses and uses the cell to replicate. Recent evidence suggests that in response to the pulmonary infection of Mycobacterium tuberculosis, the peripheral macrophages matures into M1 phenotype. Macrophage M1 phenotype is characterized by increased secretion of pro-inflammatory cytokines (IL-1β, TNF-α, and IL-6) and increased glycolytic activities essential for clearance of infection.

=== Ruminants === Cattle that consume bracken ferns develop acute bracken poisoning and chronic bovine enzootic haematuria (BEH). The main feature of acute bracken poisoning in cattle is the depression of bone marrow activity, which gives rise to severe leucopenia (particularly of the granulocytes), thrombocytopenia, and acute haemorrhagic crisis. However, most of the researchers believe ptaquiloside is not the direct causing agent of the acute bracken fern poisoning. The main feature of haematuria is urinary bladder tumors and haematuria in cattle after prolonged exposure to bracken. Based on the extensive studies, a positive correlation is shown between the ptquiloside concentration and the incidence of BEH.

=== Emulsification === Sorbitan monooleate is used to stabilize emulsions by facilitating the mixture of non-miscible components like oil and water. It is particularly effective in forming stable W/O emulsions. It reduces the interfacial tension between oil and water phases in an emulsion. This lowered tension helps prevent the separation of the two phases, promoting a more stable emulsion.

Sources: en.wikipedia.org

Further detail

In 1983, financier Marc Rich was accused of violating the act by trading in Iranian oil during the Iran hostage crisis. He was one of many people pardoned by President Bill Clinton in his last days in office. On August 23, 2006, Javed Iqbal was arrested through the U.S. Department of the Treasury with a charge of conspiracy to violate the IEEPA for airing material produced by al-Manar (The Beacon) in New York City during the 2006 Israel-Lebanon conflict. On December 16, 2009, it was announced that the U.S. Department of Justice reached a settlement with Credit Suisse over accusations that the bank assisted residents of IEEPA sanctioned countries to wire money in violation of the Act from 1995 to 2006. The settlement resulted in Credit Suisse forfeiting $536 million. On July 16, 2020, a UAE-based firm, Essentra FZE Company Limited, admitted of conspiring to violate the International Emergency Economic Powers Act (IEEPA) and defying the United States sanctions on North Korea. The firm also agreed to pay a fine of $665,112 to the United States Department of Justice.

== Treatment == In most of the reported cases, the treatment options were very similar. Plasmapheresis alone or in combination with steroids, sometimes also with thymectomy and azathioprine, have been the most frequently used therapeutic approach in treating Morvan's Syndrome. However, this does not always work, as failed response to steroids and to subsequently added plasmapheresis have been reported. Intravenous immunoglobulin was effective in one case. In one case, the dramatic response to high-dose oral prednisolone together with pulse methylprednisolone with almost complete disappearance of the symptoms within a short period should induce consideration of corticosteroids. In another case, the subject was treated with haloperidol (6 mg/day) with some improvement in the psychomotor agitation and hallucinations, but even high doses of carbamazepine given to the subject failed to improve the spontaneous muscle activity. Plasma Exchange (PE) was initiated, and after the third such session, the itching, sweating, mental disturbances, and complex nocturnal behavior improved and these symptoms completely disappeared after the sixth session, with improvement in insomnia and reduced muscle twitching. However, one month after the sixth PE session, there was a progressive worsening of insomnia and diurnal drowsiness, which promptly disappeared after another two PE sessions.

=== Stress and anxiety === In vitro studies examining the effects of CRH1 antagonists on the hypothalamic–pituitary–adrenal axis showed that antalarmin inhibited ACTH release in rat anterior pituitary cells, as well as inhibited cortisol synthesis and release in human adrenal cells. In vivo studies revealed that pre-treating rats with antalarmin inhibited increases in plasma ACTH following CRH injection (i.v.), with no effect on baseline levels. However, another study demonstrated that 8 weeks of antalarmin administered twice daily (i.p.) in rats significantly lowered basal ACTH and corticosterone levels, resulting in reduced adrenocortical responsiveness to ACTH. When antalarmin was administered to primates, it also inhibited increases in plasma ACTH, as well as prevented the anxiety response produced by a social stressor (e.g. presentation of another male in an unfamiliar environment). With regards to neurochemical effects, antalarmin has been shown to inhibit increases in extracellular cortical norepinephrine induced by rat tail pinch, suggesting that CHR1 receptors may be implicated in stress-evoked norepinephrine release in the cortex. Antalarmin was also shown to have electrophysiological effects by partially reversing the inhibition of neuronal firing in the dorsal raphe nucleus that occurs following intracerebroventricular (i.c.v) administration of CRH. Studies using CRH receptor antagonists such as antalarmin in anxiety models have shown that these agents produce effects similar to clinically effective anxiolytics.

== Businesses == Golden Harvest Agro Industries Limited Golden Harvest InfoTech Limited Golden Harvest Ice-Cream Limited (Bloop) Golden Harvest Foods Limited Golden Harvest Express Golden Harvest Dairy Limited Fatehpur Estate Limited Golden Harvest Developers Limited Golden Harvest Commodities Limited Nippon Express Bangladesh Limited, a joint venture with Nippon Express. Jubilant Golden Harvest Limited, a joint venture with Jubilant FoodWorks. Cold Chain Bangladesh Limited, a joint venture with International Finance Corporation.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.

How does SR9009 work?

It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.

Is SR9009 a proven performance enhancer?

No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.

Is SR9009 approved for human use?

No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.

Network